Cargando…

Fingolimod (FTY720): First approved oral therapy for multiple sclerosis

Detalles Bibliográficos
Autores principales:	Sharma, Sushil, Mathur, A G, Pradhan, Sapna, Singh, D B, Gupta, Sparsh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications 2011
Materias:	Molecules of the Millennium
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117573/ https://www.ncbi.nlm.nih.gov/pubmed/21701650 http://dx.doi.org/10.4103/0976-500X.77118

Ejemplares similares

Boceprevir: A new hope against hepatitis C virus
por: Brashier, Dick B. S., et al.
Publicado: (2012)

Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation
por: Anantharamu, Tejus, et al.
Publicado: (2015)

Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013)

Belimumab: First targeted biological treatment for systemic lupus erythematosus
por: Dubey, Ashok K., et al.
Publicado: (2011)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis
por: Goel, Divya
Publicado: (2014)

An upcoming drug for onychomycosis: Tavaborole
por: Sharma, Neha, et al.
Publicado: (2015)

Macitentan: An important addition to the treatment of pulmonary arterial hypertension
por: Khadka, Anjan, et al.
Publicado: (2015)

Lorcaserin: A novel antiobesity drug
por: Brashier, Dick B. S., et al.
Publicado: (2014)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Ceftaroline fosamil: A novel anti-Methicillin-resistant Staphylococcus aureus cephalosporin
por: Girish, C., et al.
Publicado: (2011)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Asenapine, a new sublingual atypical antipsychotic
por: Balaraman, R, et al.
Publicado: (2010)

Belatacept: A worthy alternative to cyclosporine?
por: Melvin, George, et al.
Publicado: (2012)

Agomelatine: A novel melatonergic antidepressant
por: Manikandan, S
Publicado: (2010)

Delamanid: A new armor in combating drug-resistant tuberculosis
por: Xavier, Alphienes Stanley, et al.
Publicado: (2014)

Fospropofol
por: Mahajan, Bharti, et al.
Publicado: (2012)

Istaroxime: A rising star in acute heart failure
por: Aditya, Suruchi, et al.
Publicado: (2012)

Sofosbuvir: A novel treatment option for chronic hepatitis C infection
por: Bhatia, Harmeet Kaur, et al.
Publicado: (2014)

Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia
por: Mazhar, Faizan, et al.
Publicado: (2016)

Lifitegrast: A novel drug for treatment of dry eye disease
por: Abidi, Afroz, et al.
Publicado: (2016)

Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis
por: Mack, Heather Gwen, et al.
Publicado: (2016)

The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod
por: Patmanathan, Sathya Narayanan, et al.
Publicado: (2015)

The emerging role of FTY720 (Fingolimod) in cancer treatment
por: White, Christopher, et al.
Publicado: (2016)

The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage
por: Stradner, Martin H, et al.
Publicado: (2011)

FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination
por: Blanc, Caroline A, et al.
Publicado: (2014)

Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage
por: Xu, Hao-Liang, et al.
Publicado: (2015)

Fingolimod (FTY720) Stimulates Ca(2+)/Calcineurin Signaling in Fission Yeast
por: Hagihara, Kanako, et al.
Publicado: (2013)

FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity
por: Ahmed, Dilruba, et al.
Publicado: (2015)

The Immunosuppressant Fingolimod (FTY720) for the Treatment of Mechanical Force-Induced Abnormal Scars
por: Aoki, Masayo, et al.
Publicado: (2020)

Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy
por: Enoru, Julius O., et al.
Publicado: (2016)

FTY720-derivatives do not induce FTY720-like lymphopenia
por: Segura-Ulate, Ismael, et al.
Publicado: (2017)

FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons
por: Takasugi, Nobumasa, et al.
Publicado: (2013)

FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
por: Wang, Zifeng, et al.
Publicado: (2020)

FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value
por: Thomson, Andrew
Publicado: (2006)

Effects of FTY720 (Fingolimod) on Proliferation, Differentiation, and Migration of Brain-Derived Neural Stem Cells
por: Tan, Botao, et al.
Publicado: (2016)

Characterization of the effects of immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling pathways
por: Baer, Alan, et al.
Publicado: (2018)

Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension
por: Kira, Jun-ichi, et al.
Publicado: (2014)

Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
por: Leßmann, Volkmar, et al.
Publicado: (2023)

Effect of FTY720 (fingolimod) on graft survival in renal transplant recipients: a systematic review protocol
por: Gholamnezhadjafari, Reza, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2mq0l045ilksn6tvi0q2uvg50a